Compare WGO & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | NEO |
|---|---|---|
| Founded | 1958 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Precision Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.1M | 1.0B |
| IPO Year | 1994 | 2008 |
| Metric | WGO | NEO |
|---|---|---|
| Price | $32.41 | $9.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $42.78 | $11.14 |
| AVG Volume (30 Days) | 659.2K | ★ 1.6M |
| Earning Date | 03-25-2026 | 04-28-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | ★ 106.82 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,985,674,000.00 | N/A |
| Revenue This Year | $5.10 | $10.63 |
| Revenue Next Year | $4.69 | $9.73 |
| P/E Ratio | $89.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.40 | $4.72 |
| 52 Week High | $50.16 | $13.74 |
| Indicator | WGO | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 59.87 |
| Support Level | $28.81 | $8.68 |
| Resistance Level | $33.38 | $10.82 |
| Average True Range (ATR) | 1.36 | 0.50 |
| MACD | 0.24 | 0.14 |
| Stochastic Oscillator | 26.67 | 97.50 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.